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Sweet’s syndrome (SS) is a neutrophilic derma-
tosis characterized by an abrupt onset of painful
erythematous cutaneous lesions that have a neutro-
philic infiltrate typically located in the papillary
dermis. Fever and an elevated neutrophil count can
accompany the cutaneous manifestations. Systemic
corticosteroids are the mainstay of treatment,
although steroid-sparing agents are frequently co-
administered or substituted. We report a case of a
white man in his 60s who had a 5-year history of
SS refractory to various conventional treatments.
Rituximab, a potent B-celledepleting anti-CD20
monoclonal antibody, was initiated and resulted in
a dramatic improvement.
CASE REPORT
A 60-year-old white man presented to our clinic
with a history of abrupt onset of painful plaques with
overlying pustules on the knees, upper extremities,
and inner thighs (Fig 1). He did not have any
associated systemic symptoms. Biopsies found a
diffuse neutrophilic infiltrate with cellular debris and
edema within the papillary dermis (Fig 2). Results of
immunofluorescence studies; other autoimmune
diagnostic testing, including autoantibodies to gliadin
and transglutaminase; and special stains for microor-
ganisms (fungal, bacterial, acid-fast bacilli) were
normal. Although the patient did not have clinical
findings consistent with rheumatoid arthritis (RA),
laboratory studies found positive serologies for RA,
including rheumatoid factor (RF) of 238 U/mL
(normal,\20 U/mL) and anticyclic citrullinated pep-
tide antibodies (anti-CCP) of 125 units (normal,\19
units). Age-appropriate malignancy workup and
evaluation for other systemic disorders were normal.
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bmc.edu.the diagnosis of SS. SS was confirmed after the patient
was treated with prednisone (1 mg/kg) and dapsone
(100 mg/d), and his lesions cleared within a few
weeks of therapy.
When prednisone was tapered, he had an exac-
erbation of his cutaneous SS. Dyspnea also devel-
oped, which was initially attributed to the anemia
from dapsone. As the dyspnea worsened, he was
evaluated by the pulmonology department and was
found to have interstitial lung disease. Over the next
year, dapsone was discontinued, and the patient did
not respond to colchicine (0.12 mg/d) and myco-
phenolate mofetil (2.5 g/d). Joint pain developed,
and RA was diagnosed by his rheumatologist. He
subsequently did not respond to hydroxychloro-
quine (400mg/d), and developed side effects to both
etanercept and adalimumab. Because he was still on
prednisone, 20 mg/d, and given his history of RA and
interstitial lung disease, he was treated with ritux-
imab (RA protocol, ie, 1000 mg at days 1 and 15).1
Four months after his initial rituximab treatment, the
patient was able to taper his prednisone to 4 mg/
d without any relapse of his cutaneous SS along with
improvement of his dyspnea. Because of exacerba-
tions of his arthritis, he received 2 additional cycles of
rituximab at 6 months and 18 months after the initial
dose. His cutaneous and pulmonary symptoms
continue to remain under control 22 months after
his initial rituximab treatment (Fig 3).JAAD Case Reports 2015;1:123-5.
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Fig 3. Left knee 22 months after initial rituximab dose.
Fig 1. Sweet’s syndrome. Scattered erythematous plaques
with overlying pustules on the left knee.
Fig 2. Spongiosis and a diffuse neutrophilic infiltrate with
cellular debris and edemawithin thedermis. (Hematoxylin-
eosin stain; original magnification, 340.)
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SS, or acute febrile neutrophilic dermatosis, is a
cutaneous disorder initially described in 1964 by Dr
Robert Sweet.2 The diagnosis of SS is established by
the presence of 2 major and 2 minor criteria.3 Major
criteria include (1) abrupt onset of painful erythem-
atous plaques or nodules, occasionally with vesicles,
pustules, or bullae and (2) a neutrophilic infiltrate in
the dermis without leukocytoclastic vasculitis. Minor
criteria include (1) preceding nonspecific respiratory
or gastrointestinal tract infection or vaccination orassociation with inflammatory disease, hemoproli-
ferative disorder, solid malignant tumor, or preg-
nancy; (2) constitutional symptoms and fever; (3)
leukocytosis; and (4) excellent response to treatment
with systemic corticosteroids.3
Several therapies have been described for the
management of SS. In addition to high-dose systemic
corticosteroids (1 mg/kg/d), colchicine and potas-
sium iodide are first-line treatment options.4 Second-
line therapies include nonsteroidal anti-inflammatory
drugs (eg, indomethacin, naproxen, sulindac),
dapsone, clofazimine, cyclosporine, and thalidomide.
There are reports of efficacy with methotrexate,
danazol, interferon-alfa, intravenous immunoglobu-
lins, and etetrinate.4 Lastly, biologics, including ana-
kinra and antietumor necrosis factor (TNF)-a agents,
are therapeutic alternatives.4,5 Infliximab, adalimu-
mab, and etanercept are used mainly in patients with
an associated inflammatory disease, such as inflam-
matory bowel disorder or RA.4 However, TNF-a
inhibitors have also been implicated in drug-
induced SS,6 and their use remains controversial.
This case shows that rituximab could be a treat-
ment option for recalcitrant SS. Rituximab is a
chimeric monoclonal antibody against CD20 that
causes B-cell depletion. Although it was originally
developed for the treatment of B-cell malignancies,7,8
it is also US Food and Drug Administration approved
for the treatment of RA.9 The first case report of
successful therapy of RA with rituximab was in a
patient with B-cell lymphoma and erosive arthritis
who became free of musculoskeletal symptoms
and joint inflammation.10 Subsequent randomized,
controlled studies showed response rates in RA
between 50% and 85%.1,11 It has been proposed
that rituximab improves RA by reducing the produc-
tion of T-cellemodulating cytokines, interfering with
the presentation and processing of autoantigens, and
decreasing the activation of autoreactive T cells.9 In
our patient, treatment with rituximab resulted in the
simultaneous improvement of RA and SS, suggesting
an association of these entities. However, it is unclear
why he continues to have periodic relapses of his
arthritis but no exacerbations of his cutaneous SS.
Although the pathogenesis of SS is poorly under-
stood, studies have found increased levels of pro-
inflammatory cytokines and chemokines, such as
interleukin (IL)-1, IL-8, IL-6, and IL-17; chemokine
(C-X-C motif) ligand (CXCL)-1, CXCL-2, CXCL-3, and
CXCL-16; TNF-a; and metalloproteinases.12-14 Many
of these mediators can be released from B cells15 and
may contribute to disease progression by recruit-
ment and activation of neutrophils; therefore, ritux-
imab could exert a positive effect by inhibiting the B
cells involved in the release of these mediators.
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rheumatoid arthritis along with many dermatologic
disorders including autoimmune blistering diseases,
cutaneous B-cell lymphoma, dermatomyositis, and
graft-versus-host disease.9 Until now, one other case
report has discussed the use of rituximab in neutro-
philic dermatoses. Donmez et al16 reported on a
patient with pyoderma gangrenosum (PG) associated
with granulomatous polyangitis successfully treated
with a combination of rituximab and infliximab. The
authors suggested that treatment of the underlying
disorder resulted in resolution of PG; however, it is
also possible that rituximab exerts a direct action on
PG by a mechanism that remains to be elucidated.
Based on our observations, we propose consid-
eration of rituximab as an alternative therapy in cases
of SS and other neutrophilic dermatoses unrespon-
sive to conventional therapies.
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